Streetbeat News

INVO

INVO Bioscience, Inc.

https://www.invobio.com

Industry

Medical - Devices

INVO Bioscience, Inc., a commercial-stage fertility company, provides assisted reproductive technology solutions worldwide. Its flagship product is the INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. The company was founded in 2007 and is based in Sarasota, Florida.

Open

0.86

Mkt cap

3.3M

Volume

124K

High

0.88

P/E Ratio

1.21

52-wk high

3.50

Low

0.82

Div yield

N/A

52-wk low

0.63

Invo Bioscience announced that on June 18, 2024, it received a notice from Nasdaq granting its request for continued listing on the exchange.

Portfolio Pulse from Benzinga Newsdesk

June 20, 2024 | 8:23 pm

INNO BioScience shares are trading higher after the company reported a year-over-year increase in Q1 EPS results.

Portfolio Pulse from Benzinga Newsdesk

May 16, 2024 | 11:56 am

INVO Bioscience (NASDAQ:INVO) reported a Q1 EPS loss of $(0.42) and sales of $1.58 million, marking a 352.84% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

May 15, 2024 | 8:45 pm

The article highlights the performance of 12 healthcare stocks during Wednesday's after-market session. Notable gainers include SINTX Techs (SINT), Petros Pharma (PTPI), and Bluejay Diagnostics (BJDX). Significant losers include Eyenovia (EYEN), Lucy Scientific Discovery (LSDI), and Monte Rosa Therapeutics (GLUE).

Portfolio Pulse from Benzinga Insights

May 15, 2024 | 8:32 pm

INVO Bioscience's short interest has risen by 39.13%, with 17,000 shares sold short, representing 0.64% of its float. This increase in short interest could indicate bearish sentiment among investors. However, INVO's short interest is still lower than its peer group average of 2.05%.

Portfolio Pulse from Benzinga Insights

May 15, 2024 | 8:15 pm

Alibaba Group Holding Limited (NYSE:BABA) shares fell by around 7% following mixed Q1 financial results. Other stocks experienced significant movements, with notable gainers including Cheetah Net Supply Chain Service Inc. (NASDAQ:CTNT) and losers like Scorpius Holdings, Inc. (NASDAQ:SCPX).

Portfolio Pulse from Avi Kapoor

May 14, 2024 | 5:30 pm

Alcon Inc. shares surged over 10% in pre-market trading due to better-than-expected Q1 earnings, with several other stocks showing significant movement based on recent performance and financial results.

Portfolio Pulse from Avi Kapoor

May 14, 2024 | 12:30 pm

In Thursday's intraday session, several healthcare stocks experienced significant movements. Aclarion, Processa Pharma, Akso Health Group, Eyenovia, Predictive Oncology, and IMAC Holdings were among the gainers, with Aclarion leading by a 66.7% increase. On the downside, Cyclacel Pharmaceuticals, Organogenesis Holdings, Xylo Technologies, Protagenic Therapeutics, American Oncology Network, and INVO Bioscience saw notable declines, with Cyclacel Pharmaceuticals dropping by 33.1%.

Portfolio Pulse from Benzinga Insights

April 25, 2024 | 4:31 pm

In Friday's pre-market session, several healthcare stocks showed significant movement. Chromocell Therapeutics, Kineta, Portage Biotech, Erasca, MSP Recovery, and Cue Health were among the gainers, with increases ranging from 12.25% to 21.6%. On the downside, Nexalin Technology, iSpecimen, INVO Bioscience, Intelligent Bio Solutions, Trevena, and PaxMedica experienced declines between 9.58% and 18.4%. Notably, MSP Recovery and INVO Bioscience had recent earnings reports influencing their stock movements.

Portfolio Pulse from Benzinga Insights

April 19, 2024 | 12:08 pm

In Thursday's intraday session, several healthcare stocks experienced significant movements. Bio-Path Holdings, Aileron Therapeutics, 23andMe Holding, SINTX Techs, iSpecimen, and Benitec Biopharma were among the gainers, with increases ranging from 25.62% to 67.1%. On the downside, SeaStar Medical Holding, Aptorum Group, NRX Pharmaceuticals, Genetic Technologies, Ontrak, and INVO Bioscience saw declines between 20.34% and 27.0%. These movements were influenced by recent earnings reports and market dynamics.

Portfolio Pulse from Benzinga Insights

April 18, 2024 | 4:31 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.